152 related articles for article (PubMed ID: 36010999)
21. Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3.
Lin PH; Lin CC; Yang HI; Li LY; Bai LY; Chiu CF; Liao YM; Lin CY; Hsieh CY; Lin CY; Ho CM; Yang SF; Peng CT; Tsai FJ; Yeh SP
Leuk Res; 2013 Mar; 37(3):287-92. PubMed ID: 23276395
[TBL] [Abstract][Full Text] [Related]
22. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
23. Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.
Schwartz GW; Manning B; Zhou Y; Velu P; Bigdeli A; Astles R; Lehman AW; Morrissette JJD; Perl AE; Li M; Carroll M; Faryabi RB
Clin Cancer Res; 2019 Jan; 25(2):573-583. PubMed ID: 30181385
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
Antar A; Kharfan-Dabaja MA; Mahfouz R; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):298-302. PubMed ID: 25550214
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
[TBL] [Abstract][Full Text] [Related]
26. Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia.
Schiller J; Praulich I; Krings Rocha C; Kreuzer KA
Eur J Haematol; 2012 Jul; 89(1):53-62. PubMed ID: 22458420
[TBL] [Abstract][Full Text] [Related]
27. [Influence of FLT3-ITD Mutation and ITD Length on the Outcome on Patients with Acute Myeloid Leukemia].
Chen F; Jiang XJ; Yin CX; Zhong QX; Jiang L; Yu GP; Sun J; Meng FY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):678-683. PubMed ID: 29950203
[TBL] [Abstract][Full Text] [Related]
28. [Clinical characteristics and prognosis of 34 cases of acute myeloid leukemia with FLT3 internal tandem duplication and MLL gene rearrangement].
Zhou JR; Zhang X; Zhao YL; Yang JF; Zhang JP; Cao XY; Lu Y; Liu DY; Lyu FY; Ouyang J; Lu PH
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):751-756. PubMed ID: 30369187
[No Abstract] [Full Text] [Related]
29. Is allogeneic transplantation really the best treatment for FLT3/ITD-positive acute myeloid leukemia? A systematic review.
Ma Y; Wu Y; Shen Z; Zhang X; Zeng D; Kong P
Clin Transplant; 2015 Feb; 29(2):149-60. PubMed ID: 25430616
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of low allelic ratio
Sakaguchi M; Yamaguchi H; Najima Y; Usuki K; Ueki T; Oh I; Mori S; Kawata E; Uoshima N; Kobayashi Y; Kako S; Tajika K; Gomi S; Shono K; Kayamori K; Hagihara M; Kanda J; Uchiyama H; Kuroda J; Uchida N; Kubota Y; Kimura S; Kurosawa S; Nakajima N; Marumo A; Omori I; Fujiwara Y; Yui S; Wakita S; Arai K; Kitano T; Kakihana K; Kanda Y; Ohashi K; Fukuda T; Inokuchi K
Blood Adv; 2018 Oct; 2(20):2744-2754. PubMed ID: 30341082
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
32. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
[TBL] [Abstract][Full Text] [Related]
33. FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients.
Zhang YY; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Sun YQ; Liu KY; Huang XJ
Bone Marrow Transplant; 2019 Sep; 54(9):1462-1470. PubMed ID: 30710101
[TBL] [Abstract][Full Text] [Related]
34. Which FLT3 Inhibitor for Treatment of AML?
Senapati J; Kadia TM
Curr Treat Options Oncol; 2022 Mar; 23(3):359-380. PubMed ID: 35258791
[TBL] [Abstract][Full Text] [Related]
35. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
[TBL] [Abstract][Full Text] [Related]
36. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Tarlock K; Chang B; Cooper T; Gross T; Gupta S; Neudorf S; Adlard K; Ho PA; McGoldrick S; Watt T; Templeman T; Sisler I; Garee A; Thomson B; Woolfrey A; Estey E; Meshinchi S; Pollard JA
Pediatr Blood Cancer; 2015 Jun; 62(6):1048-54. PubMed ID: 25662999
[TBL] [Abstract][Full Text] [Related]
38. [Effect of FLT3-ITD with DNMT3A R882 double-mutation on the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Tang SH; Lu Y; Zhang PS; Liu XH; Du XH; Chen D; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Pei RZ; Tang XW
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):552-557. PubMed ID: 30122013
[No Abstract] [Full Text] [Related]
39. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.
Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V
J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086
[TBL] [Abstract][Full Text] [Related]
40. Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation.
Chen F; Sun J; Yin C; Cheng J; Ni J; Jiang L; Wang Q; Yu G; Wei Y; Liu X; Sun J; Carter BZ; Jiang X
Bone Marrow Transplant; 2020 Apr; 55(4):740-748. PubMed ID: 31645666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
